Merck PE Ratio 2006-2018 | MRK

Current and historical price to earnings ratio for Merck (MRK) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Merck as of August 17, 2018 is 16.44.
Merck Annual PE Ratio
Merck Quarterly PE Ratio
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $186.199B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Novartis AG (NVS) Switzerland $192.442B 16.51
AbbVie (ABBV) United States $149.625B 14.62
Novo Nordisk (NVO) Denmark $115.970B 18.54
Eli Lilly (LLY) United States $113.359B 20.98
Sanofi (SNY) France $105.440B 13.35
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
Bristol-Myers Squibb (BMY) United States $99.527B 18.01
AstraZeneca (AZN) United Kingdom $96.554B 10.62